IBDEI1L2 ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,28100,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28100,1,4,0)
 ;;=4^204.21
 ;;^UTILITY(U,$J,358.3,28100,1,5,0)
 ;;=5^Subacute LL in Remission
 ;;^UTILITY(U,$J,358.3,28100,2)
 ;;=^267526
 ;;^UTILITY(U,$J,358.3,28101,0)
 ;;=204.20^^162^1791^114
 ;;^UTILITY(U,$J,358.3,28101,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28101,1,4,0)
 ;;=4^204.20
 ;;^UTILITY(U,$J,358.3,28101,1,5,0)
 ;;=5^Subacute LL w/o Remission
 ;;^UTILITY(U,$J,358.3,28101,2)
 ;;=^336852
 ;;^UTILITY(U,$J,358.3,28102,0)
 ;;=204.22^^162^1791^112
 ;;^UTILITY(U,$J,358.3,28102,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28102,1,4,0)
 ;;=4^204.22
 ;;^UTILITY(U,$J,358.3,28102,1,5,0)
 ;;=5^Subacute LL in Relapse
 ;;^UTILITY(U,$J,358.3,28102,2)
 ;;=^336467
 ;;^UTILITY(U,$J,358.3,28103,0)
 ;;=203.02^^162^1791^102
 ;;^UTILITY(U,$J,358.3,28103,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28103,1,4,0)
 ;;=4^203.02
 ;;^UTILITY(U,$J,358.3,28103,1,5,0)
 ;;=5^Multiple Myeloma In Relapse
 ;;^UTILITY(U,$J,358.3,28103,2)
 ;;=^336462
 ;;^UTILITY(U,$J,358.3,28104,0)
 ;;=205.02^^162^1791^5
 ;;^UTILITY(U,$J,358.3,28104,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28104,1,4,0)
 ;;=4^205.02
 ;;^UTILITY(U,$J,358.3,28104,1,5,0)
 ;;=5^AML, In Relapse
 ;;^UTILITY(U,$J,358.3,28104,2)
 ;;=^336470
 ;;^UTILITY(U,$J,358.3,28105,0)
 ;;=205.12^^162^1791^50
 ;;^UTILITY(U,$J,358.3,28105,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28105,1,4,0)
 ;;=4^205.12
 ;;^UTILITY(U,$J,358.3,28105,1,5,0)
 ;;=5^CML, In Relapse
 ;;^UTILITY(U,$J,358.3,28105,2)
 ;;=^336471
 ;;^UTILITY(U,$J,358.3,28106,0)
 ;;=V10.91^^162^1791^63
 ;;^UTILITY(U,$J,358.3,28106,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28106,1,4,0)
 ;;=4^V10.91
 ;;^UTILITY(U,$J,358.3,28106,1,5,0)
 ;;=5^H/O Neuroendocrine CA Tumor
 ;;^UTILITY(U,$J,358.3,28106,2)
 ;;=^338494
 ;;^UTILITY(U,$J,358.3,28107,0)
 ;;=V10.91^^162^1791^73
 ;;^UTILITY(U,$J,358.3,28107,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28107,1,4,0)
 ;;=4^V10.91
 ;;^UTILITY(U,$J,358.3,28107,1,5,0)
 ;;=5^H/O Unspecified Malignant Neoplasm
 ;;^UTILITY(U,$J,358.3,28107,2)
 ;;=^338494
 ;;^UTILITY(U,$J,358.3,28108,0)
 ;;=465.9^^162^1792^72
 ;;^UTILITY(U,$J,358.3,28108,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28108,1,4,0)
 ;;=4^465.9
 ;;^UTILITY(U,$J,358.3,28108,1,5,0)
 ;;=5^URI
 ;;^UTILITY(U,$J,358.3,28108,2)
 ;;=URI^269878
 ;;^UTILITY(U,$J,358.3,28109,0)
 ;;=462.^^162^1792^63
 ;;^UTILITY(U,$J,358.3,28109,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28109,1,4,0)
 ;;=4^462.
 ;;^UTILITY(U,$J,358.3,28109,1,5,0)
 ;;=5^Sore Throat
 ;;^UTILITY(U,$J,358.3,28109,2)
 ;;=^2653
 ;;^UTILITY(U,$J,358.3,28110,0)
 ;;=466.0^^162^1792^2
 ;;^UTILITY(U,$J,358.3,28110,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28110,1,4,0)
 ;;=4^466.0
 ;;^UTILITY(U,$J,358.3,28110,1,5,0)
 ;;=5^Bronchitis,Acute
 ;;^UTILITY(U,$J,358.3,28110,2)
 ;;=^259084
 ;;^UTILITY(U,$J,358.3,28111,0)
 ;;=112.1^^162^1792^81
 ;;^UTILITY(U,$J,358.3,28111,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28111,1,4,0)
 ;;=4^112.1
 ;;^UTILITY(U,$J,358.3,28111,1,5,0)
 ;;=5^Vulvovaginitis,Candidal
 ;;^UTILITY(U,$J,358.3,28111,2)
 ;;=^18615
 ;;^UTILITY(U,$J,358.3,28112,0)
 ;;=616.0^^162^1792^12
 ;;^UTILITY(U,$J,358.3,28112,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28112,1,4,0)
 ;;=4^616.0
 ;;^UTILITY(U,$J,358.3,28112,1,5,0)
 ;;=5^Cervicitis
 ;;^UTILITY(U,$J,358.3,28112,2)
 ;;=^21925
 ;;^UTILITY(U,$J,358.3,28113,0)
 ;;=599.0^^162^1792^73
 ;;^UTILITY(U,$J,358.3,28113,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28113,1,4,0)
 ;;=4^599.0
 ;;^UTILITY(U,$J,358.3,28113,1,5,0)
 ;;=5^UTI
 ;;^UTILITY(U,$J,358.3,28113,2)
 ;;=UTI^124436
 ;;
 ;;$END ROU IBDEI1L2
